Aripiprazole Tablet
Product Images NDC 50090-6409

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Aripiprazole (NDC 50090-6409). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure9 (Aripiprazole Fig9)

A line graph depicting the change in YGTSS total TIC score from baseline over 8 weeks of treatment. The graph compares three groups: Aripiprazole low dose, Aripiprazole high dose, and placebo, showing least-squares mean change in total TIC score on the vertical axis and weeks of treatment on the horizontal axis.*

FDA Label Image

Figure4 (Aripiprazole Fig4)

A chart titled 'Aripiprazole Fold Change and 90% CI' showing fold changes in pharmacokinetic parameters (AUC and Cmax) relative to a reference across various special populations. The populations assessed include CYP2D6 poor vs. extensive metabolizers, gender (female vs. male), age (18-64 vs. over 65), hepatic impairment (mild, moderate, severe vs. normal), and severe renal impairment, with error bars representing 90% confidence intervals.*

FDA Label Image

Figure5 (Aripiprazole Fig5)

A pharmacokinetic (PK) chart showing Dehydro-Aripiprazole fold changes with 90% confidence intervals across various factors. It compares poor versus extensive CYP2D6 metabolizers, female versus male gender, different age groups (18-64 vs. >65 years), levels of hepatic impairment (mild, moderate, severe vs. normal), and severe renal impairment, plotting their effects on AUC and Cmax relative to a reference.*

FDA Label Image

Figure6 (Aripiprazole Figure6)

A Kaplan-Meier curve graph showing the proportion of subjects with relapse over 182 days from randomization, comparing Aripiprazole and placebo groups. The X-axis represents days from randomization, and the Y-axis represents the proportion of relapse. The number of subjects at risk is shown below the X-axis for both groups at various time points.*

FDA Label Image

Figure7 (Aripiprazole Figure7)

A Kaplan-Meier plot comparing the proportion of subjects with relapse over days from randomization between Aripiprazole and placebo groups. The graph shows the number of subjects at risk at various time points up to 182 days, with Aripiprazole exhibiting a lower relapse proportion compared to placebo.*

FDA Label Image

Figure8 (Aripiprazole Figure8)

Kaplan-Meier survival curve chart comparing the proportion of patients with relapse over days from randomization between Aripiprazole and placebo groups. The x-axis shows days, and the y-axis shows the proportion with relapse. The number of subjects at risk is listed for both groups below the x-axis at various time points.*

FDA Label Image

Structure (Aripiprazole Struct)

Chemical structure of aripiprazole showing the molecular arrangement with chlorine atoms, piperazine ring, and quinolinone moiety. The diagram depicts the organic compound's key structural features relevant to its chemical identity.*

FDA Label Image

Aripiprazole_fig_01 (Aripiprazole Fig 01)

A chart titled 'Effect of Other Drugs on Aripiprazole' displaying fold changes in Aripiprazole pharmacokinetics (AUC and Cmax) with 90% confidence intervals. It compares the impact of various inhibitors, inducers, and other drugs including ketoconazole, quinidine, carbamazepine, famotidine, valproate, lithium, and lorazepam on Aripiprazole levels relative to a reference without interacting drugs.*

FDA Label Image

Aripiprazole_fig_02 (Aripiprazole Fig 02)

A chart showing the effect of various drugs on the pharmacokinetics (PK) of Aripiprazole, specifically the dehydro-aripiprazole fold change and 90% confidence interval. It compares changes in AUC and Cmax relative to a reference without interacting drug, across CYP3A4 inhibitors, CYP2D6 inhibitors, CYP3A4 inducers, gastric acid blockers, and other drugs including valproate, lithium, and lorazepam.*

FDA Label Image

Aripiprazole_fig_03 (Aripiprazole Fig 03)

A plot illustrating the pharmacokinetic effects of Aripiprazole on various drugs, showing fold changes and 90% confidence intervals in parameters like AUC and Cmax relative to reference values without interacting drugs. The drugs affected include dextromethorphan, warfarin (S- and R-isomers), omeprazole, lamotrigine, valproate, lithium, lorazepam, venlafaxine, O-desmethylvenlafaxine, and escitalopram.*

FDA Label Image

Label Image (Lbl500906409)

Label for Aripiprazole 10 mg oral tablets by A-S Medication Solutions. The label includes NDC 50090-6409, lot number, storage instructions to keep at 77 degrees Fahrenheit, and a count of 90 tablets. It also contains a QR code and directions to see the package insert.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.